Who is sponsoring ABC123?

ABC123 is sponsored by Cellectis S.A..

What condition does ABC123 study?

ABC123 studies Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

What is the status of ABC123?

ABC123 is currently TERMINATED.

Last reviewed 2019-07-31 · How we verify

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)

NCT03203369 PHASE1 TERMINATED

A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.

Details

Lead sponsor	Cellectis S.A.
Phase	PHASE1
Status	TERMINATED
Enrolment	1
Start date	Wed Jun 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions

UCART123

Countries

United States